Washington Trim Clinic Review: What Its GLP-1 Documentation Does—and Does Not—Establish

Washington Trim Clinic’s public materials answer several practical questions that weight-loss advertising often leaves vague: what medications it dispenses, what a month costs and what happens during follow-up. The more difficult question is what those documents establish about treatment outcomes. A described care process is not the same thing as independently verified clinical performance, and research on a medication does not automatically validate every preparation sold under its ingredient name.

This review examines the Bellevue, Washington, clinic’s documentation consulted October 19, 2026. Its advertised programs use compounded injectable semaglutide and tirzepatide, with physician oversight, body-composition scans and nutrition guidance. The evidence supports describing those offerings, but not assigning the clinic a success rate or independently endorsing its credentials. Our guide to what public provider documents can prove explains the distinction that matters throughout this review: documentation can establish what a business promises without proving that every promise is fulfilled.

At a glance

Documented business: Washington Trim Clinic describes itself as a physician-supervised medical weight-loss clinic in Bellevue, Washington.
Sources: [11]
Medication and monthly prices: Compounded injectable semaglutide is advertised at $299 per month and compounded injectable tirzepatide at $399 per month, each with four weekly injections and the same advertised price at any dose.
Sources: [5] [7]
Initial consultation: The clinic advertises a free, no-obligation initial consultation with its medical team, a 3D body-composition scan and a personalized treatment plan.
Sources: [12]
Follow-up structure: Monthly in-person visits are described as including a 3D scan, progress review and four weekly injections; home shipping is offered when monthly attendance is impractical.
Sources: [5] [10]
Evidence boundary: Compounded preparations are not FDA approved. FDA recommends them when a patient’s medical needs cannot be met by an approved drug; published drug trials do not establish this clinic’s outcomes.
Sources: [1] [3] [4]

Start with the actual product, not the ingredient’s reputation

Washington Trim Clinic explicitly says it dispenses compounded semaglutide and tirzepatide, and its FAQ identifies both offerings as injectable. That is a consequential disclosure: the service is not documented here as a program dispensing FDA-approved branded products. The clinic says medication arrives in a sealed vial, prepared by a licensed U.S. compounding pharmacy that it describes as LegitScript certified, with a certificate of analysis for every batch. Those are provider statements, not independently authenticated findings.

The consulted documentation does not identify the preparing pharmacy by name or address. That leaves a meaningful verification gap even though the clinic describes its pharmacy’s qualifications. A prospective patient can ask for the dispensing pharmacy’s identity, the precise formulation and an explanation of the batch documentation before accepting medication. A certificate of analysis may be relevant product documentation, but the statement that one exists does not itself establish the clinical effectiveness of the finished preparation.

FDA states that compounded preparations are not approved and do not undergo its premarket review for safety, effectiveness and quality. Nonapproval alone does not demonstrate clinical inequivalence, nor does it validate or condemn this clinic. FDA recommends compounded drugs when an individual’s needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Our explanation of approved medicines and compounded preparations separates that regulatory question from claims about outcomes.

Four evidence distinctions to keep separate
Topic	What is documented	What remains unestablished
Medication	Compounded injectable semaglutide and tirzepatide	Outcomes for the clinic’s specific preparations
Pharmacy	Provider describes a licensed U.S. compounding pharmacy	Pharmacy identity and independent credential verification
Batch documentation	Provider promises a certificate of analysis for every batch	Independent review of those certificates
Regulatory status	Compounded preparations are not FDA approved	Nonapproval alone does not prove clinical inequivalence

Sources: [5] [10] [1]

Drug research is context, not a clinic performance report

Semaglutide and tirzepatide have published randomized-trial evidence, but those studies did not test Washington Trim Clinic’s service or its compounded products. STEP 1 studied subcutaneous semaglutide in adults without diabetes over 68 weeks, alongside lifestyle intervention. SURMOUNT-1 studied subcutaneous tirzepatide in adults without diabetes over 72 weeks. Both involved defined populations and study treatments, not an open-ended endorsement of any business offering similarly named ingredients.

Tolerability also belongs in the evidence discussion. Gastrointestinal events led some participants to discontinue treatment in STEP 1, and gastrointestinal adverse events were the most common in SURMOUNT-1. Novo Nordisk funded STEP 1; Eli Lilly funded SURMOUNT-1. Their findings cannot establish results for compounded versions, different routes, microdoses or an individual patient. Nor does comparing separate trials create a randomized head-to-head comparison between the two medications.

The clinic says most patients start with semaglutide and may move to tirzepatide according to progress and response. That documents its stated approach, not proof that this sequence produces superior outcomes. Likewise, monthly scans and nutrition support describe service components rather than demonstrated effectiveness. The distinction is explored further in our guide to why a clinical trial is not a provider performance report.

Sources: [5] [10] [6] [3] [4]

What the consultation appears to involve

The initial consultation is advertised as free and without obligation, including a meeting with the medical team, a 3D body-composition scan and a personalized plan. The clinic describes reviewing a full health history, taking vital signs and using scan information to develop calorie, protein and water targets. Its medication pages also say current medicines and personal goals inform the choice of treatment. These are useful process disclosures, although they do not establish the completeness of an individual evaluation.

Both medication pages describe potential candidates as people with a BMI of at least 30, or at least 27 with a weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. Those are the clinic’s published screening thresholds, not a guarantee of eligibility. The consulted materials do not provide a minimum age, complete exclusion criteria or specific required baseline tests. NIDDK likewise emphasizes that medication selection requires consideration of health conditions, other medicines, benefits, side effects and costs.

The physician’s location during the appointment needs clarification. An institutional page advertises in-person consultations with licensed physicians, while a nutrition page describes a roughly 45-to-60-minute Bellevue visit during which the physician speaks with the patient by phone. The homepage also permits a telephone first consultation. Taken together, these statements support a mixed delivery model—not an assumption that a physician is physically present at every clinic appointment.

Sources: [12] [10] [6] [14] [7] [13] [11] [2]

The monthly offer is specific, with a few billing gaps

The published price is $299 per month for compounded injectable semaglutide or $399 per month for compounded injectable tirzepatide. Each plan lists four weekly injections, medical-team care and a body-composition scan at every visit. The clinic advertises the same price at any dose and explicitly says patients lock in their price when signing up. That is a stated commercial promise; its detailed contractual duration and exceptions are not established in the consulted documentation.

The clinic calls both programs all-inclusive, naming medication, doctor consultation, scanning and progress review. Its Trim Method also includes personalized nutrition and lifestyle guidance and in-clinic injections when needed. One cost page says there are no lab-work charges; another promises no markups on lab work. Those formulations are not identical. Patients should obtain written clarification of which tests are included, who orders them and whether an outside laboratory could bill separately.

The FAQ advertises a free first injection, describing five injections in the first month instead of four, subject to physician approval and clinic availability for same-day starting. Free consultation or injection does not mean free ongoing treatment. Also, four weekly injections are not automatically equivalent to coverage for every calendar month. The documentation does not explain the renewal date or how the monthly billing label aligns with the four-injection supply.

Sources: [7] [8] [12] [5]

Follow-up combines measurements, nutrition and access to staff

The FAQ describes one in-person visit per month for a 3D scan, progress review and medication supply. The semaglutide page identifies the scanning equipment as Styku and says it tracks fat loss versus muscle retention. The program also says it recalculates basal metabolic rate from the new scan and updates nutrition and hydration targets. These are the clinic’s descriptions of its monitoring tools; this review does not independently validate their measurement accuracy or establish muscle-protection outcomes.

Nutrition support is more concrete than a passing promise to encourage healthy habits. The clinic describes a personalized nutrition and lifestyle plan, meal guidance reflecting patients’ food traditions and help adjusting eating when appetite is low or side effects make meals difficult. However, a public Mexican-food resource marked “English and Spanish” is also labeled “Coming soon.” That does not confirm that clinical appointments, medication instructions or ongoing support are available in Spanish.

Between visits, the clinic says patients can text or call and that staff check in regularly. No guaranteed response time is documented. It also offers in-clinic injection administration at no extra charge for people who prefer not to inject themselves. These features may matter operationally, but patients should still establish who handles medication concerns and urgent questions. Our guide to clinical follow-up beyond renewal notices explains why access and clinical responsibility should be considered together.

Sources: [5] [10] [6] [8] [13]

Bellevue access is clearer than the shipping pathway

Washington Trim Clinic presents itself primarily as a local service. Its address is 13401 Bel-Red Rd, Suite A3, Bellevue, WA 98005. It mentions patients from Kirkland, Redmond, Issaquah and Mercer Island, and broadly welcomes people from Kent to Everett who can attend the clinic. Published hours are Monday through Friday, 9 a.m. to 5 p.m.; Saturday, 9 a.m. to 3 p.m. by appointment only; and closed Sunday.

The published contact paths are (425) 552-3755 and results@watrimclinic.com. For patients unable to attend monthly, the clinic says it can ship medication to their homes. That is a documented accommodation, not confirmation of nationwide service. The consulted materials do not specify authorized telehealth or shipping states, shipping fees, carrier, dispatch or arrival timelines, temperature controls or a replacement policy for delivery problems. A telephone consultation option does not resolve those geographic and logistical questions.

Delivery details matter especially for injectable medication. FDA explicitly recommends not using an injectable GLP-1 product that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy to resolve the concern. That guidance is not an allegation about this clinic’s deliveries. It identifies a practical responsibility that the clinic’s published shipping description leaves unexplained, including whom patients should contact and how a compromised shipment would be handled.

Sources: [10] [7] [11] [9] [1]

Cancellation flexibility is not a complete payment policy

The clinic describes month-to-month service with no binding commitment and says patients may pause or cancel at any time without penalties. Its pricing materials also reject enrollment fees, mandatory supplement purchases, long-term contracts and early-termination charges. Those statements are useful, but cancellation is not a refund promise. The documentation does not explain automatic renewal, collection dates, the cancellation procedure, advance-notice requirements or how already-collected payments and dispensed medication are treated.

Zero-percent financing is advertised, with available payment plans discussed during consultation. The consulted materials do not identify the financing company, eligibility requirements, repayment period or consequences of missed payments. They also do not establish a required upfront payment. Separately, the referral offer provides $50 off the next month for both people when a referred friend becomes a patient. The condition matters: merely sharing someone’s name is not the documented trigger for the benefit.

Washington Trim Clinic says most insurance plans do not cover compounded semaglutide or tirzepatide for weight loss and describes its services as HSA/FSA eligible. Those statements do not establish acceptance of a particular insurer, direct billing, reimbursement or an individual account’s payment rules. Patients should confirm coverage with their plan and account administrator rather than treating the clinic’s general affordability language as a coverage determination.

Sources: [7] [8] [2]

Credentials and long-term promises need careful attribution

The clinic says every treatment plan is prescribed and overseen by a board-certified physician licensed in Washington, while clinical staff manage appointments, scans and wellness check-ins under that supervision. It also claims LegitScript verification and compliance with HIPAA. This review did not independently verify those credentials or privacy practices. The consulted materials do not identify the supervising physician by name or provide a license number, limiting readers’ ability to connect the claims to a particular professional.

The clinic discusses both coming off medication and longer-term maintenance, saying plans depend on the patient’s situation. That is not evidence that stopping treatment will preserve weight loss. NIDDK describes obesity as a chronic disease that may require long-term care, with treatment duration depending on response and side effects. A useful consultation should therefore address ongoing clinical responsibilities and affordability, rather than presenting a target weight as a guaranteed endpoint to care.

Finally, FDA has reported measurement and administration errors involving compounded GLP-1 medication, some associated with hospitalization. Those reports are not this provider’s adverse-event rate and do not automatically establish causation. They do support asking the prescriber or pharmacist for clear product-specific instructions rather than calculating medication amounts from a review. Washington Trim Clinic’s offer of in-person administration is relevant support, but does not independently establish its medication-error performance.

Sources: [11] [5] [2] [1]

Questions & answers

Does Washington Trim Clinic offer branded or compounded medication?

Its public documentation explicitly identifies compounded injectable semaglutide and tirzepatide. It describes a sealed vial from a licensed U.S. compounding pharmacy, but does not name that pharmacy. The consulted materials do not establish a branded-drug option. Ask which exact preparation would be prescribed and which pharmacy would dispense it.

Sources: [5] [10]

What does the advertised monthly price include?

The $299 semaglutide and $399 tirzepatide programs list four weekly injections, consultation, scanning and progress review, with nutrition guidance and in-clinic administration when needed. Prices are advertised as unchanged by dose. Laboratory wording differs between pages—no charges versus no markups—so obtain a written explanation of included testing and any outside bills.

Sources: [7] [8] [12]

Will I meet the physician in person?

The documentation does not establish that for every visit. One page advertises in-person physician consultations, while another describes a Bellevue appointment with physician participation by telephone. The homepage also allows a telephone first consultation. Ask who will conduct your evaluation, where the prescriber will be and how subsequent medical reviews occur.

Sources: [11] [7] [13]

Can I receive medication without visiting Bellevue every month?

The clinic says home shipping is possible when monthly attendance is impractical. It does not publish a complete remote-care pathway or confirm eligible states, shipping charges or delivery timing. Ask how remote progress reviews replace the advertised monthly scan and visit, and obtain the pharmacy’s delivery and temperature-problem procedures before relying on shipping.

Sources: [10] [5]

Does cancel-anytime language mean I can get a refund?

No refund entitlement is established by the consulted documentation. The clinic promises month-to-month service and cancellation or pauses without penalties, but does not explain refunds, automatic renewal, billing dates or the cancellation method. Request those terms before payment, particularly if medication has already been dispensed or financing is involved.

Sources: [7] [8]

Do clinical trials establish how much weight this clinic’s patients lose?

No. STEP 1 and SURMOUNT-1 studied specified drug treatments, not Washington Trim Clinic or its compounded preparations. Their results do not establish this provider’s effectiveness or predict an individual outcome. Monthly scans document a monitoring process, but the consulted materials do not provide independently established clinic-specific outcome or tolerability rates.

Sources: [3] [4] [6]

Our assessment

Washington Trim Clinic provides a relatively concrete description of a local, medically supervised weight-management service: two named compounded injectable offerings, visible monthly prices, a free initial consultation and recurring scan-based reviews with nutrition support. Its in-clinic administration option and published contact details add practical clarity. The evidence is weaker on independently verifiable credentials, pharmacy identity, shipping safeguards and the fine print of billing and refunds. Most importantly, descriptions of monitoring and references to established medication research do not demonstrate outcomes for its own preparations. A useful next step is to request the prescriber and pharmacy identities, exact product information, written laboratory and payment terms, and the follow-up plan for side effects or delivery problems. The documentation supports evaluating this as a Bellevue-centered compounded-medication program—not treating it as a clinically validated performance claim.

Visit Washington Trim Clinic’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Washington Trim Clinic Review: What Its GLP-1 Documentation Does—and Does Not—Establish

At a glance

01Start with the actual product, not the ingredient’s reputation

02Drug research is context, not a clinic performance report

03What the consultation appears to involve

04The monthly offer is specific, with a few billing gaps

05Follow-up combines measurements, nutrition and access to staff

06Bellevue access is clearer than the shipping pathway

07Cancellation flexibility is not a complete payment policy

08Credentials and long-term promises need careful attribution